0
Comments
47
Views
The RNA-Based Vaccine Market is experiencing strong growth as messenger RNA and other RNA technologies become increasingly important platforms for vaccine development. According to WiseGuyReports, the global market was valued at approximately USD 4.6 billion in 2024 and is projected to reach USD 28 billion by 2035, representing a CAGR of about 17.9% during 2026–2035.
The rapid development of mRNA vaccines during the COVID-19 pandemic demonstrated the potential of RNA technology to accelerate vaccine development. Continued investment in biotechnology, increasing demand for personalized medicine, and expanding applications beyond infectious diseases are now creating new opportunities for the industry.
